Research Publications

Back

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months


Sosenko, JM; Skyler, JS; Beam, CA; Boulware, D; Mahon, JL; Krischer, JP; Greenbaum, CJ; Rafkin, LE; Matheson, D; HEROLD, KC; Palmer, JP; Type 1 Diabetes, TrialNet; Diabetes Prevention Trial-Type 1 Study, Groups; includes Harrison, LC
2015-05
Diabetes Care
Journal Article
38
5
940-2
OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
AMERICAN DIABETES ASSOCIATION
Population Health and Immunity
10.2337/dc14-2787
25758770
Refer to copyright notice on published article.

Back
Creation Date 2016-02-29 12:20:49 Last Modified 2019-04-01 09:03:10